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Fragile X syndrome (FXS), the most commonly inherited form of
mental retardation and autism, is caused by transcriptional silenc-
ing of the fragile X mental retardation 1 (FMR1) gene and conse-
quent loss of the fragile X mental retardation protein. Despite
growing evidence suggesting a role of specific receptors and
biochemical pathways in FXS pathogenesis, an effective therapeu-
tic method has not been developed. Here, we report that abnor-
malities in FMR1 knockout (KO) mice, an animal model of FXS, are
ameliorated, at least partially, at both cellular and behavioral
levels, by an inhibition of the catalytic activity of p21-activated
kinase (PAK), a kinase known to play a critical role in actin
polymerization and dendritic spine morphogenesis. Greater spine
density and elongated spines in the cortex, morphological synaptic
abnormalities commonly observed in FXS, are at least partially
restored by postnatal expression of a dominant negative (dn) PAK
transgene in the forebrain. Likewise, the deficit in cortical long-
term potentiation observed in FMR1 KO mice is fully restored by
the dnPAK transgene. Several behavioral abnormalities associated
with FMR1 KO mice, including those in locomotor activity, stereo-
typy, anxiety, and trace fear conditioning are also ameliorated,
partially or fully, by the dnPAK transgene. Finally, we demonstrate
a direct interaction between PAK and fragile X mental retardation
protein in vitro. Overall, our results demonstrate the genetic rescue
of phenotypes in a FXS mouse model and suggest that the PAK
signaling pathway, including the catalytic activity of PAK, is a novel
intervention site for development of an FXS and autism therapy.
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Fragile X syndrome (FXS), themost commonly inherited form ofmental retardation and the most common cause of autism, is
caused by the loss of the fragile X mental retardation protein
(FMRP) encoded by the fragile Xmental retardation 1 (FMR1) gene
(1). Although moderate to severe mental retardation and a devel-
opmental delay are the key features of FXS, patients also display
problems related to anxiety, attention deficit, hyperactivity, stereo-
typy, seizure, and social behavior. FMR1 knockout (KO) mice (2),
which exhibit phenotypes similar to those seen in FXS in humans,
have served as a useful model system for investigating how the
absence of FMRP leads to the various molecular, cellular, and
behavioral abnormalities observed in the disorder. Although these
studies have led to valuable insights into the etiology of FXS, there
has not been effective treatment of this debilitating disorder.
Several key observations are strongly suggestive of a primary role
of defects in dendritic spines and synaptic plasticity in the symptoms
associated with FXS (3). Increased numbers of dendritic spines and
an abundance of long and immature spines have been reported in
FXS individuals and FMR1 KOmice (4–7). FMRP and its mRNA
are found in dendrites and spines, the sites of transmission and
plasticity at glutamatergic synapses in the brain (8). In addition,
FMRP regulates mRNA translation, a key regulatory step in the
maintenance of long-term synaptic plasticity (9, 10). Indeed, plas-
ticity at glutamatergic synapses, such as long-term potentiation
(LTP) in the cortex and long-term depression in the hippocampus,
is abnormal in FMR1 KO mice (11–13).
The molecular underpinnings of spine abnormalities in FXS
are not well understood. However, it is known that FMRP is a
selective RNA-binding protein and can repress translation of the
bound mRNA (9, 10, 14). Some of these mRNAs encode
proteins that regulate spine morphology and/or synaptic func-
tion. In Drosophila, dFMR (the fly homologue of FMRP) binds
to the mRNA encoding small GTPase dRac, a critical regulator
of actin cytoskeletal remodeling (15). One of the main down-
stream effectors of Rac is p21-activated kinase (PAK), a family
of serine–threonine kinases that is composed of at least three
members, PAK1, PAK2, and PAK3 (16). Notably, loss-of-
function mutations in the PAK3 gene are associated with non-
syndromic X-linked mental retardation (17, 18).
Strikingly, in transgenic (TG) mice in which PAK activity is
inhibited by its dominant negative (dn) form (dnPAK), cortical
spine morphology exhibits features that are opposite to those
seen in FXS patients and FMR1 KO mice (19). Specifically,
cortical neurons in the dnPAK TG mice have fewer dendritic
spines and a lower proportion of longer and thinner spines.
These TGmice also exhibit enhanced cortical LTP in contrast to
the reduced cortical LTP observed in FMR1 KO mice. These
findings give rise to the intriguing possibility that PAK and FMR1
may antagonize each other to regulate spine morphology and
synaptic function, and therefore an inhibition of PAK activity
may lead to a correction of some of the symptoms associated with
FXS. To test this hypothesis, we attempted to rescue a range of
cellular and behavioral abnormalities observed in FMR1 KO
mice by using a genetic strategy to inhibit PAK activity.
Results
Experimental Strategy. Our strategy involved the generation of
FMR1 KO mice with inhibited PAK activity in the forebrain. To
this end, we crossed dnPAK TG mice to FMR1 KO mice to
generate littermates with four different genotypes: WT, FMR1
KO, dnPAK TG, and the double mutant dnPAK TG;FMR1 KO
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mice (dMT mice). All four genotypes are maintained in C57/B6
background. In dnPAK TG mice, reduction in PAK activity does
not start until the third postnatal week and reaches to 40%
inhibition at the second postnatal month, according to an assay
of the level of active, autophosphorylated PAK (19). We assume
the same developmental kinetics of PAK inhibition applies to
dMT mice. As discussed earlier, our aim was to test the specific
prediction that inhibiting PAK activity will rescue various phe-
notypes exhibited by the FMR1 KO mice. All experiments and
analyses were carried out ‘‘blind,’’ and the codes for the geno-
types were broken only after analysis was completed.
PAK Inhibition Partially Rescues Increased Density and Length of
Dendritic Spines in FMR1 KO Mice. Because spine abnormality is a
major pathological hallmark in FXS patients and FMR1KOmice
at the cellular level, we first examined dendritic spine morphol-
ogy by measuring spine density in apical dendrites of Golgi-
stained layer II/III pyramidal neurons of the temporal cortex of
dMTmice and their littermates, dnPAK TG, FMR1KO, andWT
mice. We quantified the number of spines per 10 m of dendritic
segments that run proximal to distal to the neuronal soma. In
proximal dendritic segments, spine density was lower in dnPAK
TG mice compared with WT mice, whereas it was higher in
FMR1 KO mice compared with WT mice (Fig. 1 A and B). In
contrast, spine density in dMT mice was comparable to that
in WT controls in all dendritic segments except segments 7 and
8 (Fig. 1B). When averaged over all segments, mean spine
density in dMT mice was significantly lower than that in FMR1
KO mice and significantly higher than that in dnPAK TG mice
(Fig. 1C). These results indicate that PAK inhibition partially
restores the abnormality of spine density in FMR1 KO mice.
In addition to an increased spine density, cortical neurons
from FXS patients and FMR1 KO mice exhibit increased spine
length (4–7). To investigate whether dnPAK can also restore this
abnormality, we measured spine length (the radial distance from
tip of spine head to dendritic shaft) of Golgi-stained pyramidal
neurons in the four genotypes. In cumulative frequency plots,
FMR1 KO neurons exhibited a significant shift in the overall
spine distribution toward spines of longer length compared with
WT neurons, whereas dnPAKTGneurons exhibited the opposite
shift to shorter spines (Fig. 1D). In contrast, spine length
distribution of dMT neurons overlapped well with that of WT
neurons (Fig. 1D), indicating that PAK inhibition is sufficient to
restore the cortical spine length abnormality in FMR1 KO mice.
PAK Inhibition Rescues Reduced Cortical LTP in FMR1 KO Mice.
Cortical LTP has been shown to be reduced in FMR1 KO mice,
whereas it is enhanced in dnPAK TG mice (12, 13, 19). To assess
the effect of PAK inhibition on the cortical synaptic transmission
and plasticity in FMR1 KO mice, we carried out extracellular
field recordings in temporal cortex layer II/III synapses while
stimulating layer IV. Basal synaptic transmission, as measured by
field potential responses to a range of stimulus intensities, did not
differ between the four genotypes (Fig. 2A). However, as
Fig. 1. PAK inhibition partially rescues increased density and length of dendritic spines in FMR1 KO mice. (A) Representative dendritic segments of layer II/III
pyramidal neurons from WT (n  20 neurons; two mice), dnPAK TG mice (n  30 neurons; three mice), FMR1 KO mice (n  20 neurons; two mice), and double
mutant dnPAK TG;FMR1 KO mice (dMT; n 40 neurons; four mice). (B) On each primary apical dendritic branch, 10 consecutive 10 m-long dendritic segments
were analyzed to quantify spine density. Spine density in dMTs was comparable to WT controls in all dendritic segments except segments 7 and 8 (P  0.05 in
segments 1–6, 9, and 10; P 0.01 in segments 7 and 8). (C) Mean spine density in dMTs (1.28 0.02) was significantly lower than that in FMR1 KO mice (1.60
0.02; P 0.001) and significantly higher than that in dnPAK TG mice (1.06 0.01; P 0.001). ANOVA, P 0.0001. ***, P 0.001. (D) As for spine length, FMR1
KO neurons (444 spines) exhibited a significant shift in the overall spine distribution toward spines of longer length compared with WT neurons (406 spines;
Kolmogorov-Smirnov test: P 0.05), whereas dnPAK TG neurons (630 spines) exhibited the opposite shift to shorter spines (P 0.01). In contrast, spine length
distribution in dMT neurons (785 spines) overlapped well with WT neurons and is significantly different from FMR1 KO neurons (P  0.01).
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expected, administration of theta-burst stimulation (TBS) at
100 Hz produced LTP of a lower magnitude in FMR1 KO mice
than in WT mice and LTP of a higher magnitude in dnPAK TG
than in WT mice (Fig. 2B). In contrast, the magnitude of LTP
was indistinguishable between dMT mice and WT controls at
various times after the application of the stimulus (Fig. 2B). This
result demonstrated that PAK inhibition rescues LTP defects in
FMR1 KO mice.
PAK Inhibition Results in a Partial Rescue of Behavioral Abnormalities
in FMR1 KO Mice. Spine morphology and synaptic plasticity are
thought to underlie learning and memory. To test whether the
partial rescue of spine morphology and the complete rescue of
cortical LTPbyPAK inhibition could ameliorate behavioral deficits
present in FMR1 KO mice, the mice of various genotypes were
subjected to a series of behavioral tasks. In an open-field test where
mice are placed in a box and allowed to run freely for 10min, FMR1
KO mice exhibited three abnormal behaviors compared with WT
mice (20): (i) hyperactivity; they traveled a longer distance and
moved for a longer period (Fig. 3A and data not shown); (ii)
stereotypy; they exhibited a higher number of repetitive behaviors
(Fig. 3B); and (iii) hypoanxiety; they stayed in the center field for
a longer period and in the corners of the field for a shorter period
(Fig. 3C and data not shown). In all three behaviors, the dMTmice
exhibited performance comparable to WT controls (Fig. 3 A–C).
This finding indicated that PAK inhibition in FMR1 KO mice
restores locomotion, repetitive behavior, and anxiety to WT levels.
Fig. 2. PAK inhibition rescues reduced cortical LTP in FMR1 KO mice. (A)
Input–output curves plotting the changes in field excitatory postsynaptic
potential (fEPSP) amplitude and their corresponding presynaptic stimulus
intensity in WT (n 45 slices; 16 mice),dnPAK TG (n 30 slices; 10 mice), FMR1
KO (n 57 slices; 19 mice), and dMT mice (n 24 slices; 8 mice). (B) Cortical LTP
induced by TBS was enhanced indnPAKTG (n13 slices; 11 mice), but reduced
in FMR1 KO (n  17 slices; 11 mice), relative to WT controls (n  17 slices; 11
mice); for responses at 55 min poststimulation, ANOVA, P  0.05; for both
dnPAK TG versus WT and FMR1 KO versus WT, P  0.04. By contrast, the
magnitude of LTP was indistinguishable between dMT slices (n  13 slices; 9
mice) and WT controls (P 0.05 for responses at 55 min poststimulation). An
overlay of representative field potential traces taken during baseline of
recording and at 55 min poststimulation is shown for each genotype.
Fig. 3. PAK inhibition partially rescues behavioral abnormalities in FMR1 KO
mice. (A–C) Open-field test (WT, n 10 mice; dnPAK TG, n 10 mice; FMR1 KO,
n11 mice; dMT,n11 mice). n.s., not statistically different.*,P0.05;***,P
0.001. (A) FMR1KO traveled a longer distance compared with WT mice (ANOVA,
P 0.01; WT, 15.29 0.92 m; FMR1KO, 20.99 1.10 m, P 0.001). (B) FMR1KO
exhibited a higher number of repetitive behaviors than WT mice (stereotypy
counts: ANOVA, P 0.05; WT, 1,636 119; FMR1 KO, 2,049 125, P 0.05). (C)
FMR1 KO stayed a longer period in the center of the open field than WT mice
(ANOVA, P 0.001; WT, 79.8 8.5 s; FMR1 KO, 143.1 12.0 s, P 0.001). In all
three behaviors, the dMT mice exhibited comparable performance to WT con-
trols (P  0.05 for all of the following parameters: distance traveled, 17.76 
0.91 m; stereotypy counts, 1,756  102; and center time, 108.8  14.6 s). (D–G)
Trace fear conditioning task (WT,n 15 mice;dnPAK TG,n 12 mice; FMR1KO,
n 15 mice; dMT, n 9 mice). n.s., not statistically different. *, P 0.05; **, P
0.01; ***, P  0.001. (D) On day 1 (conditioning), the four genotypes of mice
exhibited comparable amounts of freezing preconditioning (baseline) and post-
conditioning in all trials. (E) At the 24-h tone test, the four genotypes exhibited
comparable amounts of pretone freezing (ANOVA P  0.05). However, for
tone-dependent freezing, FMR1KO mice and dnPAK TG mice exhibited a signif-
icant reduction compared with WT controls (ANOVA for each tone session, P
0.05; for FMR1KO versus WT, P 0.05 for session 1 and P 0.01 for sessions 2–7;
fordnPAK TG versus WT, P 0.05 for session 1 and P 0.01 for sessions 2–7). The
dMT mice also showed freezing deficits during the first several tone sessions
(sessions 1–4) compared with WT controls (P 0.05). However, with additional
tone sessions (sessions 5–7), freezing by dMT mice caught up to that of WT
controls (P 0.05). (F) Average freezing for sessions 1–4. ANOVA P 0.05. The
dMTmiceshowedfreezingdeficits comparedwithWTcontrols (P0.05),but the
deficits in dMT mice were less pronounced compared with dnPAK TG (P 0.01)
or FMR1 KO mice (P 0.01). (G) Average freezing for sessions 5–7. ANOVA P
0.05. Freezing level in dMT mice was not significantly different from WT controls
(P 0.05), and there were trends in its difference from dnPAK TG (P 0.12) or
FMR1 KO mice (P 0.07).
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To further examine whether PAK inhibition can rescue ab-
normal cortex-dependent behaviors, we conducted trace fear
conditioning, a test that depends on the integrity of the pre-
frontal cortex and is sensitive to attention-distracting stimuli (21,
22). It was previously shown that FMR1 KO mice are impaired
in this form of conditioning, which may relate to the attention
deficits in FXS patients (13). In this task, a conditioning trial was
composed of a tone (as the conditioned stimulus), then a 30-s
time gap (also called trace), and finally an electric shock (as the
unconditioned stimulus). Seven trials were given to allow the
mice to learn the association between the tone and the shock
across the 30-s time gap. Mice that learn and remember this
association will become immobile (or ‘‘freeze’’) in response to
the tone, even when they are placed into a new chamber with a
different shape and smell compared with the training chamber.
During training, the four genotypes exhibited comparable
amounts of freezing in all conditioning trials (Fig. 3D), suggest-
ing normal memory acquisition. However, when placed in a new
chamber 24 h after training, both FMR1KOmice and dnPAKTG
mice exhibited a significant reduction in tone-induced freezing
compared with WT controls (Fig. 3E), indicating an impaired
trace fear memory in these two genotypes. The dMT mice also
showed freezing deficits during the first several tone sessions
(sessions 1–4) compared with WT controls (Fig. 3E), although
the deficits during these sessions were, on average, less pro-
nounced compared with dnPAK TG or FMR1KOmice (Fig. 3F).
However, with additional tone sessions (sessions 5–7), freezing
by dMT caught up to that of WT, whereas its difference from
FMR1KOmice almost reached statistical significance (P 0.07;
Fig. 3G). Thus, the dMTmice are slow in expressing the memory
and/or require a repetition of the recall cue (tone), but they can
eventually (after five tone sessions) recall the memory at the
level that is not significantly different from the WT level.
PAK1 Interacts with FMRP. The morphological, electrophysiologi-
cal, and behavioral data presented so far demonstrate that PAK
inhibition is indeed capable of rescuing, at least partially, mul-
tiple abnormalities in FMR1 KO mice. To begin to understand
the underlying mechanism, we investigated whether PAK1 (the
most abundant PAK in the brain) and FMRP physically interact.
Because PAK1 and FMRP are both localized in synapses (8, 19),
we prepared synapse-enriched membrane extract from the
mouse brain and subjected the extract to immunoprecipitation
with a PAK1 antibody (-PAK1). Proteins that may coprecipi-
tate through their direct or indirect interaction with PAK1 were
separated by SDS/PAGE and subjected to Western blot analysis
with an FMRP antibody. FMRP immunoreactivity was observed
in PAK1 immunoprecipitates but not in control serum immu-
noprecipitates (Fig. 4A Upper). This interaction is specific be-
cause it did not occur when PAK1 antibody was preincubated
with a blocking peptide, which competes with PAK1 for binding
to the PAK1 antibody, before immunoprecipitation (Fig. 4A
Upper). This result demonstrated that the endogenous PAK1 and
FMRP interact, directly or indirectly, in the brain.
To examine whether PAK1 directly interacts with FMRP, we
performed a GST pull-down assay in which in vitro-translated
FMRP was incubated with either GST or GST-tagged PAK1
(GST-PAK1). GST-PAK1, but not GST alone, bound to FMRP
[Fig. 4C and supporting information (SI) Fig. 5], suggesting a
direct interaction between PAK1 and FMRP. FMRP contains a
primary phosphorylation site at Ser-499 and three RNA-binding
domains (KH1, KH2, and RGG) that are conserved among
species (Fig. 4B) (1, 23). To map the PAK1-binding region on
FMRP, we used a series of deletion or point mutants of FMRP
in the GST pull-down assay. An FMRPmutant without the RGG
box (RGG) or phosphorylation domain containing Ser-499
(S499) was still able to bind to PAK1, whereas an FMRP
mutant without KH domains (KH) or with a point mutation in
Fig. 4. PAK1 interacts with FMRP. (A) Immunoprecipitation followed by
Western blot analysis. Brain extract was subjected to immunoprecipitation
with either rabbit serum (negative control), PAK1 antibody (-PAK1), or
-PAK1 plus a blocking peptide. Western blots were probed for either FMRP
or PAK1. For Input, 2% of the extract used for a single immunoprecipitation
was loaded on the gel. (B) Schematic structure of FMRP, highlighting various
functional domains including three RNA-binding motifs (RGG, KH1, and KH2)
and the phosphorylation site (S499, represented by a gray asterisk). The
constructs used for in vitro binding included full-length (WT), truncated
(RGG, S499, and KH), or mutated (I304N) FMRP. RGG refers to the FMRP
variant with a deletion of the RGG box at amino acids 526–555. The deleted
area in S499 spans amino acids 443–527 and includes the phosphorylation
site, S499, as well as putative phosphorylation sites. The isoleucine to aspar-
agine missense mutation in the KH2 domain mimics that previously reported
in a human FXS patient (I304N, represented by a black asterisk). The KH
deletion mutant lacks both KH domains in tandem corresponding to amino
acids 207–425. The numbers refer to the amino acid positions designated by
the SwissProt Q06787 entry. Adapted from ref. 38. (C) Characterization of the
interaction between PAK1 and various FMRP variants in vitro. In vitro-
translated FMRP variants were incubated with GST or GST-PAK1 and gluta-
thione Sepharose beads. The complexes isolated by this method were sub-
jected to SDS/PAGE and Western blotted for FMRP. For Input, 10% of in
vitro-translated FMRP sample before the binding reaction was carried out was
loaded on the gel.
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the KH2 domain previously found in a human with severe FXS
(I304N) (24) was unable to bind to PAK1 (Fig. 4 B and C). These
results suggested that PAK1 directly binds to FMRP and this
interaction requires the integrity of the KH domains of FMRP.
Discussion
In this study, we demonstrate that postnatal inhibition of cata-
lytic activity of PAK in the forebrain of FMR1 KO mice
ameliorates, at least partially, some of the FXS-related abnor-
malities present at the levels of synaptic morphology, synaptic
plasticity, and behavior. We have also provided evidence sug-
gesting that PAK and FMRP can physically interact. Taken
together, these results demonstrate the genetic rescue of phe-
notypes in a FXS mouse model and identify postnatal PAK
inhibition as a potential therapeutic strategy for countering the
various debilitating symptoms of FXS and autism.
At the moment, we do not know the precise nature of the
binding of PAK with FMRP nor the interaction between the
signaling pathways involving these proteins. Our observation
that inhibition of PAK kinase activity can counteract the deficits
in FMR1 KO mice suggests several possibilities. For instance,
PAK may repress FMRP’s activity by phosphorylating FMRP or
an upstream regulator of FMRP or a downstream effector of
FMRP. As previously shown, FMR1 KO mice exhibit enhanced
basal ERK phosphorylation (and presumably activity) (25),
whereas ERK is phosphorylated and activated by PAK at least
in non-neuronal cells (26). ERK is involved in regulation of spine
morphology, synaptic plasticity, and behaviors (27, 28); there-
fore, it is possible that PAK inhibition returns the levels of
phospho-ERK in FMR1KOmice toWT levels, thereby reversing
phenotypes in FMR1 KO mice. Alternatively, consistent with
FMRP’s role in repressing protein synthesis (9, 10, 14), FMRP
may antagonize PAK-mediated signaling by binding to and
repressing the translation of mRNAs encoding Rac1, the up-
stream activator of PAK, and possibly other components of the
PAK pathway, including cytoplasmic FMRP interacting protein
(CYFIP) and PAK itself (15, 29). Considering our in vitro
evidence of a direct interaction between PAK1 and FMRP, it is
also possible that active PAK1 binds to the KH domains of
FMRP and thereby negatively regulates FMRP’s activity by
competing with mRNAs for binding to these domains. Obvi-
ously, further study is necessary to elucidate these mechanisms.
Our in vivo data in mice suggest that treatment of FXS patients
by PAK inhibition after the appearance of disease symptoms
may be possible. FMR1 KO mice exhibit abnormalities as early
as the first postnatal week (30, 31). On the other hand, we know
that in dnPAK TG mice reduction of PAK activity does not start
until the third postnatal week and reaches to 40% inhibition
only at the second postnatal month (19). Therefore, assuming
the same developmental kinetics of PAK inhibition applies to
dMT mice, our data suggest that the phenotypes of FMR1 KO
mice could be restored, at least partially, by PAK inhibition that
did not take place until a few weeks after the appearance of
disease symptoms. In human FXS patients, symptoms like
developmental delay appear as early as 9–12 months of age and
typically diagnosis follows shortly after (32, 33). This finding
implies that PAK inhibition could be an effective postdiagnostic
therapy for FXS children. PAK inhibitors like CEP-1343 have
been described (34). Our findings warrant testing of these
inhibitors in FXS animal models with a hope of an eventual
development of an FXS drug.
In conclusion, although future studies will be necessary to
further characterize the precise molecular nature of the inter-
action between PAK and FMRP, our findings clearly demon-
strate that PAK and FMRP can exert opposing actions that form
the functional basis for reversing several key cellular and be-
havioral symptoms of FXS. In addition to their significant
therapeutic implications, these results add further evidence in
support of a primary, and potentially causal, role for defects in
spine morphogenesis in mental retardation.
Methods
Golgi Analysis. Following the Golgi-Cox technique (35), 120-m-
thick serial sections were obtained from the brains of 2-month-
old male littermates. Layer II/III pyramidal neurons in the
temporal cortex were visualized under an upright BX61 micro-
scope (Olympus, Melville, NY) with a motorized XY stage using
Neurolucida/ stereology software (Microbrightfield, Williston,
VT). On each primary apical dendritic branch, 10 consecutive 10
m-long dendritic segments were analyzed to quantify spine
density. To ensure sampling consistency between Golgi analysis
and electrophysiological experiments, analyses in the temporal
cortex were all carried out in slices or sections corresponding to
figures 62–67 of the Mouse Brain Atlas (36).
Electrophysiology. From 3-month-old male littermates, coronal
brain slices containing temporal cortex were prepared and left to
recover for at least 1 h before recording in oxygenated (95% O2
and 5% CO2) warm (30°C) artificial cerebrospinal f luid con-
taining 124 mM NaCl, 5 mM KCl, 1.25 mM NaH2PO4, 1 mM
MgCl2, 2 mM CaCl2, 26 mM NaHCO3, and 10 mM dextrose.
Field potentials in layer II/III evoked by layer IV stimulation
were measured as described (19), and responses were quantified
as the amplitude of field potential in cortex. LTP was induced by
TBS, which consisted of eight brief bursts (each with four pulses
at 100 Hz) of stimuli delivered every 200 msec.
Open-Field Test. Two-month-old male littermates were subjected
to the open-field test according to standard procedures. Each
mouse ran for 10 min in a VersaMax activity monitor chamber
(Accuscan Instruments, Columbus, OH). Open-field activity was
detected by photobeam breaks and analyzed with VersaMax
software. Stereotypy was recorded when the mouse broke the
same beam (or set of beams) repeatedly. Stereotypy count is the
number of beam breaks that occurred during this period of
stereotypic activity.
Trace Fear Conditioning Task. Three-month-old male littermates
were subjected to trace fear conditioning as described (13). On
day 1, mice were placed in the training chamber (chamber A;
Coulbourn Instruments, Allentown, PA) for 60 s before the
onset of a 15-s white noise tone (conditioned stimulus). Thirty
seconds later, mice received a 1-s shock (0.7-mA intensity;
unconditioned stimulus). Thus, one trial is composed of tone
(conditioned stimulus), 30 s of blank time (also called trace), and
then shock (unconditioned stimulus). Seven trials with an inter-
trial interval of 210 s were given to let the mice learn the
association between tone and shock across a time gap. To
examine whether mice remember this association, on day 2, mice
were placed into a new chamber (chamber B) with a different
shape and smell from those in chamber A. After 60 s, a 15-s tone
was repeated seven times with an intertrial interval of 210 s.
Video images were digitized, and the percentage of freezing time
during each intertrial interval was analyzed with the Image FZ
program (O’Hara & Co., Tokyo, Japan). Freezing was defined as
the absence of all but respiratory movement for a 1-s period.
Immunoprecipitation and Western Blotting. Mouse brains were
homogenized in ice-cold homogenization buffer [0.32 M su-
crose/10 mM TrisHCl, pH 7.4/5 mM EDTA/Complete Protease
Inhibitor Mixture Tablets (Roche, Indianapolis, IN)] and cen-
trifuged at 1,000  g for 10 min at 4°C. The supernatant was
collected and centrifuged at 21,000  g for 15 min at 4°C. The
pellet was resuspended in TE buffer (10 mM TrisHCl pH 7.4/5
mMEDTA) and one-ninth volume of cold DOC buffer (500 mM
TrisHCl, pH 9.0/10% sodium deoxycholate) was added. The
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mixture was incubated in a 37°C water bath for 30 min while
shaking andmixed with one-ninth volume of buffer T (1%Triton
X-100/1% sodium deoxycholate/500 mM TrisHCl, pH 9.0). The
membrane extract was dialyzed against binding/dialysis buffer
(50 mM TrisHCl, pH 7.4/0.1% Triton X-100) at 4°C overnight.
For immunoprecipitation, the dialyzed membrane extract was
precleared with protein A-Sepharose beads, then incubated with
-PAK1 (N-20; Santa Cruz Biotechnology, Santa Cruz, CA) or
control rabbit serum (Sigma, St. Louis, MO) in binding/dialysis
buffer for 3 h, and then incubated with protein A-Sepharose
beads overnight at 4°C. To test binding specificity, -PAK1 was
also incubated with its corresponding blocking peptide (Santa
Cruz Biotechnology) before incubation with the membrane
extract. Proteins that bound to the beads were separated by
SDS/PAGE and subjected toWestern blot analysis with -PAK1
antibody diluted at 1:1,000. For FMRP Western blots, the
membrane was processed with the Blast blotting amplification
system (PerkinElmer,Wellesley, MA) with -FMRP antibody
(Chemicon, Temecula, CA) diluted at 1:1,000.
GST Pull-Downs.GST-PAK1 plasmid was obtained from Joe Kissil
(Wistar Institute, Philadelphia, PA) (37). Plasmids encoding
FMRP and its mutants were obtained from Edouard Khandjian
(Laval University, Quebec, Canada) (38). GST and GST-PAK1
proteins were expressed in BL21 Escherichia coli, purified on
glutathione Sepharose 4B (GS4B) beads (Amersham Pharma-
cia, Piscataway, NJ), and dialyzed with PBS overnight. FMRP
and its mutants were in vitro-translated with the TNT-coupled
reticulocyte lysate systems kit (Promega, Madison, WI) and
labeled with Transcend tRNA (Promega). GST or GST-PAK1
was incubated with FMRP or its mutants in binding buffer (50
mM TrisHCl, pH 7.5/120 mM NaCl/10 mM MgCl2/5% glycer-
ol/1% Triton X-100) for 3 h. GS4B beads were added and
incubated for 1 h. Proteins that bound to the beads were
separated by SDS/PAGE and subjected to Western blot analysis
with streptavidin-horseradish peroxidase to detect in vitro-
translated FMRP or its mutants.
Animal Handling, Experimental Design, and Data Analysis.All strains
of mice were of the C57/B6 background. FMR1 KO mice were
obtained from StevenWarren (Emory University, Atlanta, GA).
dnPAK TGmice were generated in S.T.’s laboratory (19). Mouse
maintenance and all experimental procedures were performed
in compliance with National Institutes of Health guidelines. All
experiments were conducted in a blind fashion. Unless specified
otherwise, data were analyzed with Statview software (SAS,
Cary, NC) using a one-way ANOVA test followed by Fisher’s
protected least significance difference posthoc test. Values are
presented as mean  SEM.
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